According to a recent 13G filing with the US Securities and Exchange Commission, Joseph Edelman‘s Perceptive Advisors has increased its stake in Versartis Inc. (NASDAQ:VSAR) to 4.03 million common shares, which account for 13.63% of the float. The stake was raised from 2.84 million shares Perceptive Advisors previously held at the end of June, according to its last 13F filing.
Versartis is a biopharmaceutical company that primarily works on producing long-acting therapeutics for treating endocrine illnesses. Over the past 12 months, the company’s stock has gained 8.41%. In its last financial report for the second quarter of 2016, Versartis disclosed a net loss of $22.1 million and a loss per share of $0.75, which compares to a net loss of $19.7 million, and a loss per share of $0.67 for the corresponding quarter in the previous year. Recently Piper Jaffray Cos. initiated coverage on Versartis’ stock and placed an ‘Overweight’ rating on it, with a price target of $22.
RAJ CREATIONZS / shutterstock.com
Six smart money managers from Insider Monkey’s database reported long positions in Versartis (NASDAQ:VSAR) at the end of June, versus seven funds in an earlier quarter. Among bullish investors were Julian Baker And Felix Baker’s Baker Bros. Advisors, with a position valued at $30.12 million, Dennis Purcell’s Aisling Capital, which held a position valued at $25.21 million, Chuck Royce’s Royce & Associates, Mark Kingdon’s Kingdon Capital Management, and D. E. Shaw’s D E Shaw. An investor who dumped Versartis (NASDAQ:VSAR) during June quarter was Israel Englander’s Millennium Management, which said goodbye to $701,000 worth of shares.
Follow Aravive Inc. (NASDAQ:ARAV)
Follow Aravive Inc. (NASDAQ:ARAV)
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Perceptive Advisors | 0 | 4,028,685 | 0 | 4,028,685 | 13.63% | |
| Joseph Edelman | 0 | 4,028,685 | 0 | 4,028,685 | 13.63% | |
| Perceptive Life Sciences Master Fund, Ltd | 0 | 3,871,286 | 0 | 3,871,286 | 13.1% |
Follow Joseph Edelman's Perceptive Advisors
Page 1 of 8 – SEC Filing
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
13G/A
Under
the Securities Exchange Act of 1934
Versartis, Inc.
(Name
of Issuer)
Common
Stock
(Title
of Class of Securities)
92529L102
(CUSIP
Number)
September
28, 2016
(Date
of Event Which Requires Filing of this Statement)
Check the
appropriate box to designate the rule pursuant to which this Schedule is filed:
| x | Rule 13d-1(b) |
| x | Rule 13d-1(c) |
| o | Rule 13d-1(d) |
*The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the
subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided
in a prior cover page.
The
information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the Notes).
Persons
who are to respond to the collection of information contained in this form are not required to respond unless the form displays
a currently valid OMB control number.
